CJC-1295 / Ipamorelin Quick Start
This is a single co-formulated blend of two growth-hormone secretagogues that act on different receptors. CJC-1295 no-DAC (also sold as Mod GRF 1-29) is a stabilised GHRH fragment; Ipamorelin is a selective agonist at the ghrelin/GHS receptor. Pairing a GHRH analog with a GHS-receptor agonist is the standard secretagogue research approach because the two amplify each other rather than duplicating one pathway.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
CJC-1295 / Ipamorelin Composition
The product listing specifies 10 mg total per vial but does not publish the split between the two components. A 1:1 division is the common convention for this pairing; confirm the actual ratio against the batch Certificate of Analysis before treating any per-component figure as exact.
| Component | Role | Receptor | Half-life character |
|---|---|---|---|
| CJC-1295 (no-DAC) | GHRH analog | GHRH receptor | Short — ~30 min, pulse-preserving |
| Ipamorelin | Ghrelin mimetic | GHS-R1a | Short — ~2 h, selective |
CJC-1295 / Ipamorelin Dosing Protocol
The blend is dosed as one product. Ranges below are community-derived research-planning references, not personal dosing recommendations. Because both components are short-acting and the goal in the literature is to preserve the body's natural pulsatile release, dosing is timed to a natural GH pulse — bedtime, on an empty stomach.
Injection — Subcutaneous
| Band | Per dose (blend) | Frequency |
|---|---|---|
| Low | 100 mcg | Once nightly |
| Standard | 200 mcg | Once nightly |
| High | 300 mcg | Once nightly |
Cycle guidelines
| Approach | Duration | Review point | Best for |
|---|---|---|---|
| Standard | 8–12 weeks | Week 8 | General research planning |
| Extended | 12–16 weeks | Week 12 | Slower body-composition endpoints |
Off periods of 4 weeks are common in research planning. There is no published human cycling RCT for this blend.
CJC-1295 / Ipamorelin Reconstitution Guide
The blend ships as a lyophilized powder. The bacteriostatic water volume sets the concentration and the draw size; 2 mL is the common convention for a 10 mg vial.
Injection
| BAC | Conc. | 200 mcg |
|---|---|---|
| 2 mL | 5,000 mcg/mL | 0.04 mL · 4 u |
| 3 mL | 3,333 mcg/mL | 0.06 mL · 6 u |
Units are U-100 insulin-syringe units (100 u = 1.0 mL).
Per-component figures
Because the listing does not publish the split, the tables above are stated as blend totals. If the COA confirms a 1:1 division, a 200 mcg dose is 100 mcg of each component.
Reconstitution steps
- Inspect the vial. Confirm the label, expected milligram amount, and that the powder looks dry and intact.
- Wipe the stoppers. Use an alcohol swab on both the bacteriostatic water and peptide vial stoppers.
- Draw the chosen volume. 2 mL into the vial — this is the number that sets every concentration figure above.
- Inject down the wall. Release the water slowly down the inside wall, not directly onto the powder.
- Swirl, do not shake. Roll gently until dissolved. Shaking foams and can damage the peptide.
- Verify clarity. Solution should be clear and colorless. Discard if cloudy or particulate.
- Label and refrigerate. Note the date and volume added on the vial, then store at 2–8 °C. Do not freeze the reconstituted solution.
See the bacteriostatic water guide for diluent handling, or the reconstitution calculator to work any other volume.
Why These Two Together
GHRH analogs and ghrelin mimetics drive growth-hormone release through separate receptors, and combining them produces a larger release than either alone in published secretagogue work. Ipamorelin is favoured over older GHS compounds because it is selective — it does not meaningfully raise cortisol or prolactin, which was the limitation of earlier molecules in the class.
CJC-1295 no-DAC
Stimulates the GHRH receptor on the pituitary; the no-DAC form keeps the pulse short.
Ipamorelin
Selective GHS-R1a agonist; amplifies the pulse without the cortisol/prolactin rise of older GHS drugs.
Pulsatility
Both are short-acting by design — the aim is to mimic a natural pulse, not create a sustained elevation.
Open question
Long-term human data for the combination is absent; the rationale is component-level and mechanistic.
Who Should Avoid CJC-1295 / Ipamorelin
Growth-hormone-axis compounds act upstream of a broad hormonal cascade, so eligibility is a clinical question rather than a dosing one.
Active or prior cancer
Raising GH and IGF-1 is a theoretical proliferation concern; consistently flagged as a contraindication.
Diabetes or insulin resistance
GH is counter-regulatory to insulin and can worsen glycaemic control.
Pregnancy & lactation
No human safety data.
Tested athletes
GH secretagogues are prohibited in sport under WADA S2; use is an anti-doping rule violation.
CJC-1295 / Ipamorelin Side Effects & Safety
Injection-site reactions
Redness or itching at the site is the most commonly reported short-term effect; rotate sites.
Water retention & tingling
Mild oedema, joint aches or carpal-tunnel-type tingling are classic GH-axis effects and are dose-related.
Glycaemic effects
GH opposes insulin; glucose handling can shift, which matters most for anyone already insulin-resistant.
Quality-control risk
A blend cannot be visually distinguished from a single peptide — verify identity and per-component purity against a COA.
CJC-1295 / Ipamorelin Evidence Context
Ipamorelin pharmacology
Characterised as a selective GHS-R agonist that raises GH without the cortisol and prolactin effects of earlier compounds.
GHRH analog literature
CJC-1295 and Mod GRF 1-29 have published pharmacokinetic work showing GH and IGF-1 elevation.
Combination data
Human trial data for this specific co-formulation is absent; the rationale is component-level.
Open question
Whether pulsatile secretagogue elevation produces the outcomes attributed to it has not been established in controlled trials.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C, protected from light | More stable than reconstituted solution. |
| Reconstituted (liquid) | 2–8 °C | −20 °C for longer storage per the listing. |
| Appearance | Clear, colorless | Discard cloudy or particulate solutions. |
Blend vs Sermorelin
| Feature | CJC-1295 / Ipamorelin | Sermorelin |
|---|---|---|
| Composition | GHRH analog + ghrelin mimetic | GHRH analog alone |
| Receptors | GHRH-R and GHS-R1a | GHRH-R only |
| Rationale | Two pathways amplify the pulse | Single-pathway, closest to native GHRH |
| Page | This page | Sermorelin |
Frequently Asked Questions
Is this two separate vials?
No. It is a single co-formulated blend — one 10 mg vial containing both peptides, dosed as one product.
How much of each component is in a dose?
The listing publishes only the 10 mg total, not the split. A 1:1 division is the common convention, which would make a 200 mcg dose 100 mcg of each — but confirm against the batch COA rather than assuming.
Why dose at bedtime?
Both components are short-acting and the approach in the literature is to amplify a natural GH pulse. The largest natural pulse occurs shortly after sleep onset, and food blunts the response.
How is it reconstituted?
10 mg in 2 mL of bacteriostatic water gives 5,000 mcg/mL, so a 200 mcg dose is 4 units on a U-100 syringe.
Is it banned in sport?
Yes. Growth-hormone secretagogues fall under WADA category S2 and are prohibited at all times.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
CJC-1295 / Ipamorelin Formats & Sourcing
The blend is supplied as a lyophilized powder in a single 10 mg vial. There is no pre-reconstituted pen or spray format for this product. Batch-specific Certificates of Analysis are issued per lot and are the place to confirm the component split.
| Format | Supplied as |
|---|---|
| Vial | 10 mg total lyophilized blend |
Strengths are listed as sold; confirm against the product page and the batch COA before calculating anything.
Reference material for this protocol, with batch COA:
View CJC-1295 / Ipamorelin on Spyro Peptides →References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998).
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab (2006).
- Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues. Transl Androl Urol (2020).
- World Anti-Doping Agency. Prohibited List 2025 — S2 peptide hormones and growth factors.